Setmelanotide, administered subcutaneously [SC], once daily.
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
20
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Bardet-Biedl Syndrome (BBS)
Conditions
Bardet-Biedl Syndrome (BBS), Obesity
Trial Timeline
— → —
NCT ID
NCT05183802About Setmelanotide, administered subcutaneously [SC], once daily.
Setmelanotide, administered subcutaneously [SC], once daily. is a pre-clinical stage product being developed by Rhythm Pharmaceuticals for Bardet-Biedl Syndrome (BBS). The current trial status is completed. This product is registered under clinical trial identifier NCT05183802. Target conditions include Bardet-Biedl Syndrome (BBS), Obesity.
Hype Score Breakdown
Clinical
5
Activity
2
Company
7
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05183802 | Pre-clinical | Completed |
Competing Products
2 competing products in Bardet-Biedl Syndrome (BBS)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Setmelanotide 2 mg + Setmelanotide 2.5 mg + Setmelanotide 3 mg + Setmelanotide 20 mg + Setmelanotide 25 mg + Setmelanotide 30 mg | Rhythm Pharmaceuticals | Phase 3 | 74 |
| Setmelanotide | Rhythm Pharmaceuticals | Phase 3 | 74 |